Clinical Trial: Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Naltrexone and Lofexidine in Detoxified Heroin Addicts
Brief Summary: Stress is one of the more common reasons cited by addicts for continual drug use and relapse. Treatment approaches that target both drug-induced and stress-induced relapse may prove to be more beneficial than targeting drug-induced relapse alone. Lofexidine is a drug that reduces the physical symptoms of opiate withdrawal and may prove to have stress-reducing capabilites in drug addicts. The purpose of this study is to determine the maximal safe dose of lofexidine tolerated in naltrexone-treated heroin addicts and to find an optimal lofexidine induction schedule.
Detailed Summary:
Stress is one of the more common reasons cited by addicts for continual drug use and relapse. Naltrexone treatment of opiate addicts suffers from high rates of drop-out and relapse. This may be a result of naltrexone's inability to reduce symptoms of stress during early recovery. Treatment approaches that target both drug-induced and stress-induced relapse may prove to be more beneficial than targeting drug-induced relapse alone. Lofexidine is a drug that reduces the physical symptoms of opiate withdrawal and may prove to have stress-reducing capabilities. The purpose of this study is to determine the maximal safe dose of lofexidine tolerated in naltrexone-treated opiate addicts and to find an optimal lofexidine induction schedule. The study will also assess any side effects that occur during a discontinuation phase of lofexidine.
This pilot study will last a total of 8 weeks. Recently detoxified opiate dependent participants who are eligible for naltrexone treatment will enter a 4-week single-blind dose tolerability phase, during which participants will receive naltrexone and 1 of 3 twice-daily lofexidine induction schedules. All participants will be required to remain in the clinic for 2 hours immediately following dosing in order to monitor vital signs and side effects. Study visits will occur three times each week, at which time naltrexone medication for self-administration will be handed out and participants will be evaluated in terms of tolerability to treatment. After the 4 weeks of treatment, a double-blind lofexidine detoxification phase using a 5-day taper will occur. Participants will be randomly assigned to one of two maintenance-taper schedules. The first group will undergo a 5-day tapering, followed by a placebo for three weeks, followed by a 5-day tapering during Week 4. Withdrawal symptoms and side effects will be evaluated.
Sponsor: National Institute on Drug Abuse (NIDA)
Current Primary Outcome:
- Retention in treatment; measured throughout 8 weeks
- Frequency and amount of opiate use; measured weekly
- Stress levels; measured weekly
Original Primary Outcome: Same as current
Current Secondary Outcome: Tolerability; measured throughout 8 weeks
Original Secondary Outcome: Same as current
Information By: National Institute on Drug Abuse (NIDA)
Dates:
Date Received: September 16, 2005
Date Started: March 2003
Date Completion: September 2004
Last Updated: January 11, 2017
Last Verified: October 2016